Tags

Type your tag names separated by a space and hit enter

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.
J Clin Virol. 2020 07; 128:104443.JC

Authors+Show Affiliations

Clinical Associate Professor in Infectious Diseases, Department of Internal Medicine, Alabama Infectious Diseases Center, 420 Lowell Drive Suite 301, Huntsville, AL, 35801, USA. Electronic address: ali_hasoun@yahoo.com.Department of Internal Medicine, University of Alabama at Birmingham, School of Medicine - Huntsville Regional Medical Campus, 301 Governor's Drive, Huntsville, AL, 35801, USA. Electronic address: lisa.thottacherry@gmail.com.Huntsville Hospital Department of Pharmacy, Huntsville Hospital Health Systems, 101 Sively Rd SW, Huntsville, AL, 35801, USA. Electronic address: justin.muklewicz@hhsys.org.Department of Internal Medicine, University of Alabama at Birmingham, School of Medicine - Huntsville Regional Medical Campus, 301 Governor's Drive, Huntsville, AL, 35801, USA. Electronic address: qaziz04@gmail.com.Huntsville Hospital Department of Pharmacy, Huntsville Hospital Health Systems, 101 Sively Rd SW, Huntsville, AL, 35801, USA. Electronic address: jonathan.edwards@hhsys.org.

Pub Type(s)

Letter
Comment

Language

eng

PubMed ID

32425661

Citation

Hassoun, Ali, et al. "Utilizing Tocilizumab for the Treatment of Cytokine Release Syndrome in COVID-19." Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, vol. 128, 2020, p. 104443.
Hassoun A, Thottacherry ED, Muklewicz J, et al. Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19. J Clin Virol. 2020;128:104443.
Hassoun, A., Thottacherry, E. D., Muklewicz, J., Aziz, Q. U., & Edwards, J. (2020). Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19. Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 128, 104443. https://doi.org/10.1016/j.jcv.2020.104443
Hassoun A, et al. Utilizing Tocilizumab for the Treatment of Cytokine Release Syndrome in COVID-19. J Clin Virol. 2020;128:104443. PubMed PMID: 32425661.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19. AU - Hassoun,Ali, AU - Thottacherry,Elizabeth Dilip, AU - Muklewicz,Justin, AU - Aziz,Qurrat-Ul-Ain, AU - Edwards,Jonathan, Y1 - 2020/05/16/ PY - 2020/05/07/received PY - 2020/05/13/accepted PY - 2020/5/20/pubmed PY - 2020/6/20/medline PY - 2020/5/20/entrez SP - 104443 EP - 104443 JF - Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology JO - J Clin Virol VL - 128 SN - 1873-5967 UR - https://www.unboundmedicine.com/medline/citation/32425661/Utilizing_tocilizumab_for_the_treatment_of_cytokine_release_syndrome_in_COVID_19_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1386-6532(20)30185-2 DB - PRIME DP - Unbound Medicine ER -